Format

Send to

Choose Destination
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):18-25. doi: 10.1016/j.mce.2014.03.007. Epub 2014 Apr 2.

C/EBPβ knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NFκB.

Author information

1
Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu 611130, China.
2
Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
3
Department of Pharmacy, Changsha Central Hospital, Changsha 410004, China.
4
Department of Pharmacy, Guangdong No.2 Provincial People's Hospital, Guangzhou 524000, China.
5
Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu 611130, China.
6
Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: chshaor@mail.sysu.edu.cn.
7
Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: liupq@mail.sysu.edu.cn.

Abstract

C/EBPβ, a member of the bHLH gene family of DNA-binding transcription factors, has been indicated as a central signal in physiologic hypertrophy. However, the role of C/EBPβ in pathological cardiac hypertrophy remains to be elucidated. In this study, we revealed that C/EBPβ is involved in cardiac hypertrophy, the expression of C/EBPβ were significantly increased in response to hypertrophic stimulation in vitro and in vivo. C/EBPβ knockdown inhibited PE-induced cardiac hypertrophy, and diminished the nuclear translocation and DNA binding activity of p65-NFκB. These results suggested that C/EBPβ knockdown protected cardiomyocytes from hypertrophy, which may be attributed to inhibition of NFκB-dependent transcriptional activity. These findings shed new light on the understanding of C/EBPβ-related cardiomyopathy, and suggest the potential application of C/EBPβ inhibitors in cardiac hypertrophy.

KEYWORDS:

C/EBPβ; Cardiac hypertrophy; p65-NFκB

PMID:
24704266
DOI:
10.1016/j.mce.2014.03.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center